HomeAI · summaries
Storia in 3 fonti
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Biogen (NASDAQ:BIIB)
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
- ·
endpoints.news
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand in I&I.
